History
A journey with many milestones
PTC Therapeutics
A Brief History of Innovation
PTC Therapeutics was founded in 1998 focused on leveraging its expertise in RNA biology to discover and develop treatments for patients living with rare diseases.
In the first 25 years, PTC achieved historic breakthroughs in the treatment of several rare diseases.
PTC is looking forward to the next quarter century, utilizing its expanded scientific expertise and strong commercial infrastructure to continue in its mission of developing treatments for more patients living with rare diseases.
2023
- Matthew B. Klein, M.D. appointed Chief Executive Officer
- PTC celebrates its 25th anniversary and 10 years as a public company
2021
- Received Gallup’s “Don Clifton Strengths-Based Culture” Award
2020
- Expanded clinical pipeline to include potential treatments for further rare diseases.
2019
- Expanded platform technologies with the acquisition of a ferroptosis & inflammation platform to address diseases of oxidative stress
2013
- Successful IPO in the US public markets (NASDAQ: PTCT)
2010
- Awarded grant from the Wellcome Trust that supported research and development
1998
- PTC was founded with the mission to discover, develop, and commercialize treatments for patients with rare disorders